Trailing-twelve-month (TTM) revenue is $450.89 Million with a year-over-year growth of +16.77%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $110,329,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $125,215,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-19 |
| Q1 FY2026Period ended 2026-03-31 | $94,473,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $120,877,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $450,894,000 |
Current P/S: $809,019,975 market capitalization ÷ $450,894,000 TTM revenue = 1.79x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:15:24.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $120.88M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:15:43.776Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Collaborative Development | N/A | $4M | $0 | $0 | N/A | N/A |
| License | $706,000 | $5M | $35M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Asia Pacific | $7M | $10M | $37M | $41M | $78,000 | $29M |
| CANADA | N/A | $13,000 | $31,000 | N/A |
$450.89M
$450.89 Million
+16.77%
vs. $386.14M a year ago (TTM)
+105.14%
5 Year compound annual growth rate
1 Year
+16.77%
3 Year
+75.86%
5 Year
+105.14%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $407.32M | +$73.70M | +22.09% |
| 2024 | $333.62M | +$209.16M | +168.06% |
| 2023 | $124.46M | +$72.30M | +138.61% |
| 2022 | $52.16M | +$42.06M | +416.57% |
| 2021 | $10.10M | +$2.53M | +33.36% |
| 2020 |
TTM Growth
+16.77%
3-Year CAGR
+75.86%
5-Year CAGR
+105.14%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 35 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:15:43.776Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $36M |
| $78,000 |
| $5M |
| Product | $1M | N/A | $16M | $83M | $319M | $378M |
|---|
| Product, IBSRELA | N/A | N/A | N/A | $80M | $158M | $274M |
|---|
| N/A |
| N/A |
| North America | $806,000 | N/A | N/A | $59,000 | $14M | $342,000 |
|---|
| UNITED STATES | N/A | $0 | $16M | $83M | $319M | $378M |
|---|
| $7.57M |
| +$2.29M |
| +43.36% |
| 2019 | $5.28M | +$2.67M | +102.57% |
| 2018 | $2.61M | ($39.39M) | (93.79%) |
| 2017 | $42.00M | +$17.97M | +74.81% |
| 2016 | $24.03M | $0 | +0.00% |
